Breast Cancer Index predicts pathological complete response and eligibility for breast conserving surgery in breast cancer patients treated with neoadjuvant chemotherapy-Reference-Cited by-同舟云学术

Breast Cancer Index predicts pathological complete response and eligibility for breast conserving surgery in breast cancer patients treated with neoadjuvant chemotherapy

Published:2012-08 Issue:8 Volume:23 Page:2046-2052
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Mathieu M.C.,Mazouni C.,Kesty N.C.,Zhang Y.,Scott V.,Passeron J.,Arnedos M.,Schnabel C.A.,Delaloge S.,Erlander M.G.,André F.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/23/8/2046/313890/mdr550.pdf

Reference23 articles.

1. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update;Kaufmann;J Clin Oncol,2006

2. Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22;Fisher;J Clin Oncol,1997

3. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27;Rastogi;J Clin Oncol,2008

4. Proceedings of the consensus conference on neoadjuvant chemotherapy in carcinoma of the breast, April 26-28, 2003, Philadelphia, Pennsylvania;Schwartz;Cancer,2004

5. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis;Mauri;J Natl Cancer Inst,2005

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular subtype identification and prognosis stratification based on lysosome-related genes in breast cancer;Heliyon;2024-02

2. The neoadjuvant systemic treatment of early breast cancer: a narrative review;Annals of Breast Surgery;2023-12

3. Nomogram to predict pathological axillary lymph node status after neoadjuvant therapy in triple negative or HER2 positive breast cancer;2023-07-11

4. A novel cuproptosis-related prognostic 2-lncRNAs signature in breast cancer;Frontiers in Pharmacology;2023-01-09

5. Tailoring neoadjuvant treatment of HR-positive/HER2-negative breast cancers: Which role for gene expression assays?;Cancer Treatment Reviews;2022-11